10 Oct '18
Primer Capital, a Russian venture fund, has invested $200,000 in a California-based company called MatriSys Bioscience, a spokesperson for the Russian fund told Marchmont News.
The investee is developing the MSB-01, a drug candidate that is said to effectively kill a highly aggressive strain of Staphylococcus aureus, a bacterium that is often responsible for damaging the skin of atopic dermatitis (eczema) patients. The MSB-01 helps restore a normal microbiome (microbiota) of the skin, the developers claim. (A microbiota includes bacteria, archaea, protists, fungi and viruses, and has been found to be crucial for immunologic, hormonal and metabolic homeostasis of its host – Editor’s note.)
MatriSys Bioscience is currently completing its I/IIà phase clinical trials for the MSB-01 candidate in the United States. The new investment is expected to be used for putting together a IIb clinical trial phase and funding the company’s R&D in the field of bacterial therapy of a range of other dermatological diseases.
Primer Capital’s portfolio now includes ten projects from Russia, the U.S., Israel, and France.
“Molecular bacterial therapy is a new and promising approach to treating chronic skin disorders. Based on our scientific expertise, and knowing the high market demand for research and development in atopic dermatitis therapy, we can expect this project to show high investment potential,” Primer Capital Executive Director Elizaveta Rozhdestvenskaya said in a comment on the deal.
Atopic dermatitis is a chronic and relapsing disease that manifests itself in a wide range of symptoms from small-area inflammations next to knees and elbows to sweeping lesions across 90+% of the skin. The industrially developed countries of Europe and North America report the 25% incidence of the disease.
Set up three years ago, Primer Capital is focused on investing in companies that develop far-reaching biotech and medical solutions for a range of the pharma market segments.